Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

Pancreatic cancer is one of the most lethal of human malignancies, and potent therapeutic options are lacking. Inhibition of cell cycle progression through pharmacological blockade of cyclin-dependent kinases (CDK) has been suggested as a potential treatment option for human cancers with deregulated...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Feldmann, Georg, Mishra, Anjali, Bisht, Savita, Karikari, Collins, Garrido-Laguna, Ignacio, Rasheed, Zeshaan, Ottenhof, Niki A, Dadon, Tikva, Alvarez, Hector, Fendrich, Volker, Rajeshkumar, NV, Matsui, William, Brossart, Peter, Hidalgo, Manuel, Bannerji, Rajat, Maitra, Anirban, Nelkin, Barry D
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2011
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3218385/
https://ncbi.nlm.nih.gov/pubmed/21768779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.12.7.16475
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars